Role of paraoxonase-1 in CYP2C19 loss-of-function carriers.
Clinical Pharmacology and Toxicology Service, Geneva University Hospitals and Faculty of Medicine, Switzerland; Geneva Platelet Group, Faculty of Medicine and University Hospitals of Geneva, Geneva, Switzerland. Electronic address: Youssef.Daali@hcuge.ch.
Y
Y
Daali
Geneva Platelet Group, Faculty of Medicine and University Hospitals of Geneva, Geneva, Switzerland; Division of Angiology and Haemostasis, Geneva University Hospitals and Faculty of Medicine, Switzerland.
J L
JL
Reny
Geneva Platelet Group, Faculty of Medicine and University Hospitals of Geneva, Geneva, Switzerland; Division of Internal Medicine, and Rehabilitation, Trois-Chênes, University Hospitals of Geneva, Geneva, Switzerland.
P
P
Fontana
D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics*; D043303:Aryldialkylphosphatase / Q000378:metabolism*; D001241:Aspirin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D013927:Thrombosis / Q000188:drug therapy*; D013988:Ticlopidine / Q000031:analogs & derivatives*
D010975:Platelet Aggregation Inhibitors; D001189:Aryl Hydrocarbon Hydroxylases; D043303:Aryldialkylphosphatase; D013988:Ticlopidine; D001241:Aspirin